Details of the Drug Reposition

General Information of This Drug (ID: DMZ2YBE)

Drug Name
Lexipafant   DMZ2YBE
Synonyms
LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Nerve injury DISZ919E ND56.4 Phase 2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatovirus infection DISQJJ4C 1E51 Investigative [2]
------------------------------------------------------------------------------------

References

1 Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.
2 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.